GRI Bio, Inc. SEC filings GRI
GRI Bio, Inc. has 402 filings in SEC EDGAR's recent list, going back to Sep 11, 2020. Its latest annual report, Form ARS, was filed on Sep 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (officer or director change, shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Sep 28, 2026 | Nov 4, 2026 |
| DEF 14A | Proxy statement | Dec 29, 2025 | Jan 15, 2026 |
| PRE 14A | Preliminary proxy statement | Dec 19, 2025 | Dec 19, 2025 |
| DEF 14A | Proxy statement | Jul 11, 2025 | Aug 13, 2025 |
| DEF 14A | Proxy statement | Jan 17, 2025 | Feb 11, 2025 |
| PRE 14A | Preliminary proxy statement | Jan 7, 2025 | Feb 11, 2025 |
| DEFA14A | Additional proxy material | Aug 23, 2024 | — |
| DEFA14A | Additional proxy material | Aug 23, 2024 | — |
| DEFA14A | Additional proxy material | Aug 16, 2024 | — |
| DEF 14A | Proxy statement | Aug 2, 2024 | Aug 23, 2024 |
| PRE 14A | Preliminary proxy statement | Jul 23, 2024 | Aug 23, 2024 |
| DEF 14A | Proxy statement | May 9, 2024 | May 9, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 29, 2024 | Apr 26, 2024 |
| DEFA14A | Additional proxy material | Jan 8, 2024 | — |
| DEF 14A | Proxy statement | Jan 2, 2024 | Jan 2, 2024 |
| PRE 14A | Preliminary proxy statement | Dec 20, 2023 | Dec 20, 2023 |
| DEFA14A | Additional proxy material | May 26, 2023 | — |
| DEF 14A | Proxy statement | May 26, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 5, 2023 | — |
| DEFA14A | Additional proxy material | Apr 5, 2023 | — |
| DEFA14A | Additional proxy material | Apr 3, 2023 | — |
| DEFA14A | Additional proxy material | Mar 30, 2023 | — |
| DEFA14A | Additional proxy material | Mar 23, 2023 | — |
| DEF 14A | Proxy statement | Jun 6, 2022 | Jul 13, 2022 |
| PRE 14A | Preliminary proxy statement | May 25, 2022 | Jul 13, 2022 |
| DEFA14A | Additional proxy material | Apr 27, 2022 | — |
| DEF 14A | Proxy statement | Apr 27, 2022 | Dec 31, 2021 |
Showing 27 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GRI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1824293
- Former names
- Vallon Pharmaceuticals, Inc. (until Apr 21, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.